MicroRNAs (miRNA) are small non-coding RNAs involved in post-transcriptional gene regulation that have crucial roles in several types of tumors, including papillary thyroid carcinoma (PTC). miR-146b-5p is overexpressed in PTCs and is regarded as a relevant diagnostic marker for this type of cancer. A computational search revealed that miR-146b-5p putatively binds to the 3 0 untranslated region (UTR) of SMAD4, an important member of the transforming growth factor b (TGF-b) signaling pathway. The TGF-b pathway is a negative regulator of thyroid follicular cell growth, and the mechanism by which thyroid cancer cells evade its inhibitory signal remains unclear. We questioned whether the modulation of the TGF-b pathway by miR-146b-5p can contribute to thyroid tumorigenesis. Luciferase reporter assay confirmed the direct binding of miR-146b-5p on the SMAD4 3 0 UTR. Specific inhibition of miR-146b-5p with a locked nucleic acid-modified anti-miR-146b oligonucleotide significantly increased SMAD4 levels in the human papillary carcinoma cell lines, TPC-1 and BCPAP. Moreover, suppression of miR-146b-5p increased the cellular response to the TGF-b anti-proliferative signal, significantly decreasing the proliferation rate. The overexpression of miR-146b-5p in normal rat follicular PCCL3 cells decreased SMAD4 levels and disrupted TGF-b signal transduction. MiR146b-5p overexpression in PCCL3 cells also significantly increased cell proliferation in the absence of thyroidstimulating hormone and conferred resistance to TGF-bmediated cell-cycle arrest. Additionally, the activation of thyroid most common oncogenes RET/PTC3 and BRAF in PCCL3 cells upregulated miR-146b-5p expression. Our results confirm the oncogenic role of miR-146b-5p in thyroid follicular cells and contribute to knowledge regarding the modulation of TGF-b signal transduction by miRNAs in PTCs.
Introduction
MicroRNAs (miRNAs) are a class of small non-coding RNAs that are involved in post-transcriptional gene regulation via imperfect pairing with the 3 0 untranslated region (UTR) of target mRNAs. In mammalian cells, miRNAs drive repression of gene expression by inhibiting protein translation and, less frequently, by mRNA degradation. MiRNAs mediate several biological processes including cell growth, apoptosis, cell differentiation, and development (Bartel, 2004) . In addition, miRNAs participate in cancer initiation, progression, and metastasis (Calin and Croce, 2006; Dykxhoorn, 2010) . The regulation of classical oncogenes and tumor suppressor genes by miRNAs was rapidly identified as a cancer hallmark, transforming this class of small RNAs into potential targets for cancer therapy, diagnosis, and prognosis.
Thyroid cancer is the most common endocrine malignancy and accounts for 45% of cancers in women. In the United States, B1690 deaths are estimated to result from thyroid cancer in 2010 (Jemal et al., 2010) . Papillary thyroid carcinoma (PTC) is the most prevalent type of tumor among thyroid malignancies, accounting for B80% of cases. The most common genetic alterations involved in PTC development preferentially lead to the constitutive activation of the RET-RAS-BRAF-MAPK signaling pathway. These alterations include RET/PTC rearrangements (Santoro et al., 2002) , the BRAF V600E point mutation , and, less frequently, RAS mutations (Fagin, 2002) . Although these genetic alterations lead to the activation of the same signaling pathway, they are mutually exclusive and rarely overlap.
Large-scale analyses have described the deregulation of several miRNAs in thyroid tumor samples (He et al., 2005; Nikiforova et al., 2009; Pallante et al., 2010) , revealing that the 5 0 strand of miR-146b, miR-146b-5p, is upregulated in PTCs and can be used as a diagnostic tool for this type of cancer. However, it has not been confirmed whether upregulation of this miRNA in PTC exerts a causative effect on thyroid malignant transformation. Using programs available online, we determined that both isoforms of miR-146, a and b, potentially regulate the SMAD4 gene. The regulation of SMAD4 by miR-146a has been described previously in a promyelocytic leukemia cell line (Zhong et al., 2010) . SMAD4 (SMAD family member 4/Mothers against decapentaplegic homolog 4) is an important effector of the transforming growth factor b (TGF-b) signaling pathway. TGF-b is a member of the homonymous TGF-b superfamily, which includes activins (ACT) and bone morphogenetic protein, among others (Massague, 1998) . The activation of TGF-b signal transduction in epithelial cells begins when TGF-b binds to its type II receptor (TbRII), which then recruits the type I receptor (TbRI), leading to the phosphorylation of receptorregulated SMADs 2 and 3 (R-SMADs). TGF-b signal transduction is mostly mediated by SMAD4, which associates with the phosphorylated R-SMADs (pSMADs) and translocates to the nucleus to drive the transcriptional regulation of several target genes.
Under normal physiological conditions, TGF-b is a potent inhibitory factor of epithelial cells, including thyroid follicular cells (Heldin et al., 2009) . Despite its anti-proliferative activity, expression of TGF-b1 is elevated in thyroid carcinomas, suggesting that tumor cells become unresponsive to the TGF-b inhibitory signal (Kimura et al., 1999) . Although chromosomal deletions involving the SMAD4 locus are frequently found in pancreatic adenocarcinomas, metastatic colorectal cancers, and small intestinal carcinomas , these deletions are rarely observed in thyroid tumors. In a subset of thyroid tumors, inactivating mutations and alternative splicing are observed in the SMAD4 gene, resulting in decreased gene expression levels (Lazzereschi et al., 2005) . Thus, the molecular events that cause thyroid tumor cells to lose responsiveness to the TGF-b anti-proliferative signal are not fully understood.
The aim of the present study was to analyze the influence of miR-146b-5p on the regulation of TGF-b signal transduction and to determine its contribution to thyroid tumorigenesis. We overexpressed the miR146b-5p in the normal rat thyroid follicular cell line, PCCL3, and used a locked nucleic acid-modified antimiR-146b oligonucleotide to inhibit this miRNA in the human papillary carcinoma cell lines, TPC-1 and BCPAP. Our data suggest an important role of miR146b-5p in the regulation of SMAD4, and consequently, in the modulation of the TGF-b signaling pathway in normal and tumoral thyroid cell lines.
Results
Oncogenic activation of the RET-RAS-BRAF-MAPK signaling pathway in normal thyroid follicular cell lines induces upregulation of miR-146b-5p The abnormal expression of miR-146b-5p has been reported previously in association with the most frequent oncogenic events observed in PTC: the BRAF V600E point mutation and RET/PTC rearrangements (Santoro et al., 2002; Kimura et al., 2003; Cahill et al., 2006; Nikiforova et al., 2008; Chou et al., 2010) . We observed that the activation of both RET/PTC3 and BRAF oncogenes in PCCL3 cells led to the upregulation of miR-146b-5p expression (Figure 1 ). SMAD4 modulation by miR-146b-5p in normal and tumoral thyroid cell lines To test whether miR-146b-5p can regulate SMAD4 expression through the binding to its 3 0 UTR, a wild type and a mutated binding site of miR-146b-5p on SMAD4 3 0 UTR were cloned into a luciferase reporter plasmid, generating the plasmids pmiRGlo-SMAD4-3 0 UTR-wt and -Mut, respectively (Figure 2a) . To avoid the interference of endogenous SMAD4 transcript, the luciferase assays were performed in the ARO cell line, which express low SMAD4 levels. The co-transfection of pmiRGlo-SMAD4-wt with pcDNA-miR-146b led to a reduction in the luciferase activity (Figure 2b ). In contrast, the transfection of anti-miR-146b restored luciferase activity to control levels. Moreover, miR146b-5p was not able to bind to the mutated construct.
To investigate the role of miR-146b-5p in normal rat follicular cells (PCCL3), we generated the conditionally miR-146b-5p-expressing cell line PC-146b (Figure 2c ). To analyze the role of miR-146b-5p on thyroid cancer cells, we used a specific miR-146b-5p oligonucleotide inhibitor (anti-miR-146b) to deplete miR-146b-5p expression in two papillary carcinoma cell lines, TPC-1 and BCPAP (Figure 2d ). Quantitative PCR and western blot analysis revealed that overexpression of miR-146b-5p in PC-146b cells decreased Smad4 expression at the transcriptional and translational levels (Figures 2e  and f) . On the other hand, the suppression of miR-146b-5p by anti-miR-146b in both TPC-1 and BCPAP cells led to a marked increase in SMAD4 mRNA and protein levels (Figures 2e and f) .
Modulation of the TGF-b signaling pathway by miR146b-5p To verify the influence of Smad4 modulation by miR146b-5p on TGF-b signal transduction in PC-146b cells, overexpression of miR-146b-5p was induced with DOX for 72 h, and recombinant TGF-b1 (rTGF-b1) was added to the culture. Given its regulation by the TGF-b signal (Matsuo et al., 2006) , SMAD4 expression was 
The predicted binding site of miR-146b-5p on SMAD4 3 0 UTR was cloned in pmiRGlo plasmid, generating the pmiRGlo-SMAD4-3 0 UTR-wt plasmid. A plasmid containing the mutated binding site (shown as asterisks) was used as control (pmiRGlo-SMAD4-3 0 UTR-Mut). (b) The luciferase assay was performed in the SMAD4-deficient ARO cells. The respective luciferase reporter plasmid was transfected alone (SMAD4-wt, SMAD4-Mut); co-transfected with pcDNA3.1-miR146b (SMAD4-wt þ miR146b, SMAD4-Mut þ miR146b); with anti-miR-146b (SMAD4-wt þ miR146b þ Anti-146b) or pcDNA3.1-miR-21 (SMAD4-wt þ miR-21). (c) Total RNA extracted from rat follicular cells PC-146b, grown in the presence (DOX) or absence (CTR) of doxycycline for 0, 24, 48, 72, and 96 h was used for quantification of miR-146b-5p expression. (d) Human papillary thyroid carcinoma cell lines TPC-1 and BCPAP were transfected with anti-miR-146b oligonucleotide (10 or 25 nM). Each cell line incubated with transfection reagent alone or transfected with the commercially available negative control anti-miR-1 were used as reference (mock) and negative control (neg), respectively. (e) PC-146b cells were treated with DOX or control (CTR) for 72 h (0, 0.1, or 1 mg/ml) and TPC-1 and BCPAP cells were transfected (anti-146b) or not (mock) with antimiR-146b (0, 10, 25 nM) for 72 h for quantification of miR-146b-5p and SMAD4 gene expression. (c, e) SnoRNA (Rattus norvegicus Small nucleolar RNA) and RPL19 (Rattus norvegicus ribosomal Protein L19) gene expression were used for rat miRNA and mRNA normalization, respectively. (d, e) RNU6B (Homo sapiens Small nuclear RNA U6) and RPL19 (Homo sapiens ribosomal protein L19) genes were used as internal controls for human miRNA and mRNA expression. (f) For PAGE analyses, 40 mg of total protein per sample were used. a-TUBULIN expression was used for normalization. Data are represented as average of three independent experiments and bars represent standard deviation. *Po0.05; **Po0.01; ***Po0.001. miR-146b-5p disrupts TGF-b signal transduction MV Geraldo et al despite the increase in TGF-b1 mRNA levels ( Figure 3b ). Suppression of miR-146b-5p increased the response of TPC-1 cells to the TGF-b signal, significantly increasing SMAD4 gene expression levels in response to rTGFb1 treatment when compared with cells treated with rTGF-b1 alone ( Figure 3c ). Depletion of miR-146b-5p in TPC-1 cells increased gene expression of CDKN1A, even though TGF-b1 levels were slightly decreased ( Figure 3d ). Moreover, treatment of TPC-1 cells with rTGF-b1 and anti-miR-146b for 1 h resulted in strong translocation of SMAD4 to the nucleus, as observed by laser confocal microscopy, when compared with treatment with rTGF-b1 alone ( Figure 4a ). To confirm these data, we conducted immunoblotting experiments using nuclear and cytoplasmic protein fractions isolated from these groups. As expected, increased nuclear accumulation of SMAD4 was observed following transfection with anti-miR-146b and treatment with rTGF-b1 ( Figure 4b ). The suppression of miR-146b-5p also markedly increased the activity of a TGF-bresponsive luciferase reporter construct, p3TP-Lux ( Figure 4c ). To determine whether the nuclear accumulation of SMAD4 could restore the transduction of TGF-b inhibitory signal, TPC-1 cells transfected with anti-miR-146b were treated with rTGF-b1 or control, and the MTT assay was performed. AntimiR-146b transfection significantly increased sensitivity to the TGF-b anti-proliferative signal, indicating that miR-146b-5p inhibition was sufficient to reestablish TGF-b signal transduction after 24 h of treatment ( Figure 4d ).
PCCL3 cells retain the expression of the thyroidspecific differentiation genes Nis, Tg, Tpo, and Tshr in vitro (Fusco et al., 1987) . We tested whether the modulation of TGF-b by miR-146b-5p could influence expression of these genes. The overexpression of miR146b-5p in PC-146b cells increased mRNA levels of all of thyroid-specific genes ( Figure 5a ). However, the western blot analysis revealed no significant alterations of NIS protein levels ( Figure 5c ) in PC-146b cells. The inhibition of miR-146b-5p in the tumor cell line, TPC-1, decreased Tg mRNA levels ( Figure 5b ). The expression levels of NIS, TPO, and TSHR were not detectable in mock cells or in miR-146b-5p-suppressed TPC-1 cells. No detectable levels of NIS protein were observed in TPC-1 cells.
MiR-146b-5p promotes cell growth by abrogating cellular responsiveness to the TGF-b signal We next analyzed the influence of miR-146b-5p on cellcycle regulation of normal thyrocytes. The addition of doxycycline to the culture medium has been described as inadequate for cell-cycle and proliferation analyses miR-146b-5p disrupts TGF-b signal transduction MV Geraldo et al because of its intrinsic cytotoxicity (Ermak et al., 2003) . Therefore, we generated the cell line PC-CMV-146b, which stably expresses miR-146b-5p independently of DOX treatment (Figure 6a ). PC-CMV-146b cells were synchronized by serum and thyroid-stimulating hormone (TSH) deprivation, and cell-cycle reentry was Anti-146b + rTGF-β1 miR-146b-5p disrupts TGF-b signal transduction MV Geraldo et al evaluated 3, 6, and 12 h later. Twelve hours after stimulation, 80% of PC-CMV-146b cells sorted to a predominant G 0 /G 1 peak, and 20% of cells sorted to the S/G 2 /M peak. In contrast, PCCL3 cells transfected with empty vector (PC-CMV-+) were distributed 84% to the G 0 /G 1 phase and 16% to the S/G 2 /M phase (Po0.001). We then tested whether the ablation of TGF-b signal transduction by miR-146b-5p is sufficient to promote cell-cycle progression under exogenous TGF-b stimulation. As expected, PC-CMV-+ cells treated with rTGF-b1 exhibited a strong response to the TGF-b inhibitory signal, characterized by cell-cycle arrest, with 85% of cells in G 0 /G 1 and 15% of cells in S/G 2 /M. In contrast, the overexpression of miR-146b-5p conferred resistance to the TGF-b signal, displaying, after 12 h stimulation, 20% of cells in S/G 2 /M (Po0.001). Western blot analysis confirmed that PC-CMV-146b cells did not respond to TGF-b signal, exhibiting higher Cyclin D1 levels after treatment with rTGF-b1 for 24 h (Figure 6b ). PCCL3 cell growth is dependent on TSH (Fusco et al., 1987) . The overexpression of miR-146b-5p reversed the cell-cycle arrest mediated by TSH deprivation, with 31% of cells in the S/G 2 /M phase vs 22% of PC-CMV-+ cells in S/G 2 /M (Figure 6c) .
Flow cytometry analysis revealed no significant changes in the response to TGF-b-mediated apoptosis by overexpression or suppression of miR-146b-5p in PC-CMV- 146b and TPC-1 cells, respectively (Figures 7a and b) .
We then investigated if cell-cycle deregulation caused by miR-146b-5p-mediated disruption of the TGF-b pathway could interfere with cell growth potential. PC-CMV-146b cells displayed significantly higher proliferation rates when compared with PC-CMV-+ cells (Figure 7c ). Importantly, miR-146b-5p overexpression also promoted cell proliferation in the absence of TSH stimulation. In contrast, TPC-1 and BCPAP cells transfected with anti-miR-146b exhibited significantly decreased cell growth after 48 h (Figure 7c ). 
(+) PC-CMV-+ cells, (+ þ rTGFb1) PC-CMV-+ cells plus rTGF-b1 (1 ng/ml), (miR-146b) PC-CMV-146b cells, (miR-146b þ rTGFb1) PC-CMV-146b cells plus rTGF-b1 (1 ng/ml). (b)
For PAGE analysis, 30 mg of total protein extracts per sample from PC-CMV-+ (+) and PC-CMV-146b (miR-146b) treated or not with rTGF-b1 (1 ng/ml) for 12 h was used for immunoblotting. The blot was incubated with specific antibody against Cyclin D1. Incubation of the blot with specific antibody against a-Tubulin was used for normalization. (c) PC-CMV-+ and -146b cells were grown in the absence of FBS and TSH for synchronization of cells in the G 0 /G 1 phase. After 24 h, the culture medium was replaced by FBS with (TSH( þ )) or without (TSH(À)) TSH. Cells were collected 72 h after replacement of medium and were fixed, RNase treated, and stained with PI for cell-cycle analysis. Histograms display cell count in y axis and PI fluorescence in x axis. The data shown are representative of three independent experiments performed in duplicates. Two-way ANOVA test: + vs + þ TGF-b Po0.001; + vs miR-146b Po0.001; + þ TGF-b vs miR-146b þ TGF-b Po0.001.
Taken together, these results suggest that modulation of the TGF-b signaling pathway by miR-146b-5p overexpression is sufficient to generate a TGF-b-resistant phenotype in thyroid follicular cells that promotes tumor cell proliferation.
Discussion
The overexpression of miR-146b-5p has been observed frequently in PTCs (Pallante et al., 2010) . To date, however, the relationship between miR-146b-5p and papillary carcinoma was not fully understood. Our results suggest an oncogenic role for miR-146b-5p in normal and tumoral thyroid cells, as a negative regulator of the TGF-b signaling pathway.
Thyroid gland growth is stimulated mainly by TSH, via TSH receptor (TSHR)-mediated increases in cAMP and subsequent activation of the PKA pathway (GarciaJimenez and Santisteban, 2007) . Although normal thyrocyte growth is tightly controlled by TGF-b (Taton et al., 1993 ) the overexpression of miR-146b-5p in PC-CMV-146b cells increased TSH-independent cell growth and generated a TGF-b-resistant phenotype. Therefore, miR-146b-5p may confer enhanced replicative potential to thyroid tumor cells through the ablation of TGF-b autocrine and paracrine loops. Moreover, alterations in the MAPK cascade resulting from RET/PTC rearrangements or RAS-or BRAF-activating point mutations are present in 470% of PTCs (Adeniran et al., 2006) . As we observed, the induction of the oncogenes RET/PTC3 and BRAF V600E in PCCL3 cells led to the upregulation of miR-146b-5p (Figure 1) . Therefore, in thyroid tumors, the activated MAPK cascade confers positive growth advantages not only by increasing the cell proliferation rate, but also by indirectly inhibiting the TGF-b antiproliferative signal via upregulation of miR-146b-5p. To our knowledge, this is the first functional demonstration of the importance of the MAPK pathway in the induction of miR-146b-5p expression in thyroid cells. A computational analysis of the promoter region of miR-146b using TFSEARCH program (Heinemeyer et al., 1998) revealed specific sequence motifs for NFkB and MAPK signaling-related transcription factors (for example, c-ETS and AP-1), suggesting a potential direct and indirect regulation by MAPK pathway. In fact, it has been reported that both miR-146a/b genes are transcriptionally regulated by NFkB in innate and acquired immune responses (Taganov et al., 2006) . In thyroid cancer cells, NFkB signaling is activated by the BRAF V600E mutation to increase invasiveness and promotes tumor growth and resistance to chemotherapy via the upregulation of miR-146a (Palona et al., 2006; Pacifico et al., 2010) .
Notably, miR-146b-5p upregulation is not observed in other tumors. In glioma cell lines, hormone-refractory prostate tumors, and metastatic breast cancer cell lines, miR-146b-5p is reported to be downregulated, acting as a tumor suppressor gene (Bhaumik et al., 2008; Hurst et al., 2009; Xia et al., 2009 ). These contrasting roles may be explained by the differences regarding the targets repressed by miR-146b-5p in each tissue. miR146b-5p may be associated with a complex network of gene expression regulation that could be tissue and stage dependent, targeting different mRNA species in each circumstance. Similarly, the TGF-b pathway has contrasting roles in cancer, acting as a tumor suppressor in epithelial-derived tumors and as a tumor-promoter factor in mesenchyme-derived tumors and epitheliumderived tumors undergoing epithelial-to-mesenchymal transition (Massague, 2008) . The modulation of the TGF-b pathway by miR-146b-5p could be, therefore, a unique event in thyroid tissue.
The TGF-b signaling pathway strongly inhibits cell growth in epithelial cells mainly by downregulating the protooncogene MYC and upregulating cyclindependent kinase inhibitor CDKN1A (Siegel and Massague, 2003; Pei and Xiong, 2005) . The proliferative potential of tumor cells depends on their ability to disrupt TGF-b signal transduction and bypass TGF-bmediated cell-cycle arrest. Overexpression of miR-146b-5p in PC-146b cells was associated with increased expression of c-Myc, whereas the inhibition of miR146b-5p in TPC-1 increased CDKN1A expression. Moreover, the overexpression of miR-146b-5p in PC-CMV-146b cells reversed TGF-b-mediated cell-cycle arrest, indicating impairment of the TGF-b antiproliferative signal.
TGF-b is also an important regulator of thyrocyte differentiation (Taton et al., 1993) by negatively regulating the sodium/iodine symporter (NIS) (Kawaguchi et al., 1997) , TSHR (Morris et al., 1988) , thyroperoxidase (TPO) (Franzen et al., 1999) , and thyroglobulin (TG) (Nicolussi et al., 2003) . This control is driven by TGF-b through the SMAD-mediated transcriptional inhibition of the transcription factors PAX-8 and TITF-1 (Nicolussi et al., 2003; Costamagna et al., 2004) . Accordingly, NIS, TPO, TG, and TSHR were upregulated in response to overexpression of miR-146b-5p in PC-146b cells. However, the overexpression of miR146b-5p was not sufficient to induce detectable changes in NIS protein levels in PC-146b cells, maybe due to NIS protein half-life, estimated in 5 days (Paire et al., 1997) . In contrast, in TPC-1 cells, suppression of miR146b-5p decreased TG mRNA levels, although NIS, TPO, and TSHR were undetectable. Interestingly, the induction of the BRAF V600E mutation in PCCL3 cells represses NIS in a TGF-b-dependent manner (RiescoEizaguirre et al., 2009) , indicating that the TGF-b pathway may have a dual role in regulation of thyroid differentiation.
Genetic alterations in the SMAD4 gene have been reported in pancreatic and gastro-intestinal tract carcinomas . Although it is believed that loss of SMAD4 is not a critical step for cancer initiation, tumor cells bearing other oncogenic pathways develop a more aggressive phenotype in the absence of this molecule. In thyroid tumors, alternative splicing and inactivating mutations combine to decrease SMAD4 gene expression (Lazzereschi et al., 2005) . As we demonstrated, the inhibition of miR-146b-5p in the papillary miR-146b-5p disrupts TGF-b signal transduction MV Geraldo et al papillary carcinoma cell lines, BCPAP and TPC-1. The restoration of SMAD4 levels increased the responsiveness of the TGF-b pathway, decreasing cell migration and proliferation. In this context, elevated expression of miR-146b-5p could be a key factor in thyroid cancer progression, decreasing SMAD4 levels to overcome the TGF-b inhibitory signal. We have previously shown that SMAD4 may be present in thyroid tumors (Matsuo et al., 2010) , suggesting that other factors may be involved in thyroid tumorigenesis. Because the overexpression of inhibitory SMAD7 (SMAD7) has been reported in thyroid tumor samples and cell lines (Cerutti et al., 2003; Matsuo et al., 2010) , regulation of the TGF-b pathway by SMAD7 and other regulatory proteins may also take part in the refractoriness to the TGF-b signal by thyroid tumor cells. Furthermore, crosstalk between the TGF-b signaling pathway and several other cancer-related pathways may contribute to the disruption of the TGF-b signal (Ellenrieder, 2008) . It is important to note that TGF-b signal transduction can also be driven via a non-SMAD pathway (Moustakas and Heldin, 2005) .
The human miR-146 family comprises two miRNA genes located on different chromosomes: miR-146a at 5q34, and miR-146b at 10q24.32. Both isoforms have been described as deregulated in tumors. Recently, in an acute promyelocytic leukemia model, luciferase experiments revealed that miR-146a negatively regulates SMAD4 by binding to its 3 0 UTR (Zhong et al., 2010) . However, in PTCs, the miR-146b, rather than miR-146a, is predominantly deregulated.
This study highlights the functionality of miR-146b in thyroid gland oncogenesis. The disruption of TGF-b signal transduction caused by overexpression of miR-146b may be a relevant step for thyroid tumor cells, contributing to PTC establishment and progression. Our findings improve the understanding of the role of miRNAs in the regulation of the TGF-b signaling pathway and shed light on the molecular events related to PTC development.
Materials and methods

DNA constructs
The oligonucleotides Smad4-Fw-wt and Smad4-Rev-wt were annealed to form a segment containing the miR-146b-5p binding site on SMAD4 3 0 UTR predicted by Targetscan generating the plasmids pmiRGlo-SMAD4-3 0 UTR-wt and -Mut. The plasmids pcDNA3.1-miR-146b and -miR-21, harboring the genomic region of miR-146b-5p and miR-21, were kindly provided by Dr Konstantin D Taganov (California Institute of Technology, Pasadena, CA, USA). This plasmid pcDNA3.1-miR146b was double digested, and the insert was subsequently cloned in vector pUHG10.3 under the control of a tetracycline-responsive promoter, generating plasmid pUHG-146b. This construct was sequenced to confirm the presence of correctly oriented miR-146b-5p. The plasmid p3TP-Lux was kindly donated by Dr Joan MassaguÕ (Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA).
Cell lines and transfections PCCL3, PCCL3-rtTA, PTC3-5, TPC-1, and ARO cell lines were kindly provided by Dr James A Fagin (Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA). BCPAP cells were kindly provided by Dr Massimo Santoro (Medical School, University 'Federico II' of Naples, Naples, Italy). PTC3-5 and PC-BRAF cell lines were derived from PCCL3-rtTA cells (Saavedra et al., 2000) and conditionally express RET/PTC3 and BRAFV600E oncogenes, respectively (Wang et al., 2003; Ricarte-Filho et al., 2009) . All cell lines were maintained as described previously (Ricarte-Filho et al., 2009) . Plasmid pUHG-146b was transfected into PCCL3-rtTA cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions, to generate the PC-146b cell line. miR-146b-5p expression was induced with the addition of 1 mg/ml doxycycline (CalBiochem, San Diego, CA, USA), a tetracycline analog, to the culture medium for 72 h. Plasmid pcDNA3.1-miR-146b was transfected to PCCL3 cells to generate the PC-CMV-146b cell line. Empty pcDNA3.1 vector was transfected as control (PC-CMV-+). TPC-1 and BCPAP are human papillary carcinoma cell lines that spontaneously harbor the RET/ PTC1 rearrangement (Jhiang et al., 1992) and BRAF V600E oncogene (Fabien et al., 1994) , respectively. To inhibit miR146b-5p expression in the TPC-1 and BCPAP cell lines, antimiR-146b (Anti-miR-miRNA Inhibitor, hsa-miR-146b-5p, AM10105, Applied Biosystems, Foster City, CA, USA) was transfected at 10-25 nM concentrations using Lipofectamine 2000. TPC-1 or BCPAP cells incubated with transfection reagent alone or transfected with a commercially available negative control (anti-miR-1, AM17010; Applied Biosystems) were used as the reference (mock) and negative control (negative), respectively.
Luciferase reporter assays ARO or TPC-1 cells were seeded in 12-well plates at density of 5 Â 10 4 cells/well. After 24 h, ARO cells were transfected with the plasmids pmiRGlo-SMAD4-3 0 UTR-wt or -Mut, and pcDNA-miR-146b. The co-transfections of anti-miR-146b or the plasmid pcDNA-miR-21 were used as control. For the quantification of TGF-b pathway activity, TPC-1 cells were transfected with plasmid p3TP-Lux alone or in combination with anti-miR-146b. After 24 h, the cells were treated or not with rTGF-b1. In both assays, the cells were washed 48 h after transfection, lysed and the luciferase activity was accessed using DualGlo Luciferase Assay System (Promega) according to the manufacturer's instructions.
Treatment with recombinant TGF-b1
Recombinant TGF-b1 (rTGF-b1, Peprotech, Rocky Hill, NJ, USA) was added to culture medium at concentration 1 ng/ml. rTGF-b1 was added 72 h after induction of miR-146b-5p (PC-146b) or transfection with anti-miR-146b (TPC-1), and total RNA was extracted 3 h after for gene expression analysis or 24 h after for MTT cell proliferation assay and 1 h for immunofluorescence assay. For cell-cycle and death analysis, rTGF-b1 was added to culture 24 h after seeding.
Gene expression analysis
Total RNA was phenol-chloroform-extracted from cell lines PTC3-5, PC-BRAF, PC-146b, TPC-1, and BCPAP using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. For miRNA expression analysis, 10 ng of total RNA was reverse transcribed using a TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems) and RT primers provided with the miR-146b-5p Taqman miRNA Assay (PN4373178; Applied Biosystems) according to the manufacturer's instructions. miR-146b-5p expression was detected from the cDNA product, using TaqMan Universal PCR Master Mix No AmpErase UNG (Applied Biosystems) and the Taqman MiRNA Assay. The expression of passenger strand of miR-146b, miR-146b-3p, was not analyzed. Small nucleolar RNA, snoRNA (PN4427975; Applied Biosystems) and RNA, U6 small nuclear 2 (RNU6B) (PN4427975, Applied Biosystems) were used for the normalization of rat and human miRNA input, respectively. For mRNA expression analysis, 1 mg of total RNA was reverse transcribed using M-MLV Reverse Transcriptase (Invitrogen) according to the manufacturer's protocol, and PCR products were amplified from the cDNA using 1 Â SYBR Green Universal PCR Master Mix (Applied Biosystems) and specific primers. Ribosomal protein L19 (RPL19) was used as an endogenous control for mRNA normalization. Amplification and detection were performed using an ABI 7300 Real-Time PCR System (Applied Biosystems). MiRNA and mRNA relative quantifications were calculated based on the data generated by Sequence Detection System (Applied Biosystems) according to the Pfaffl method (Pfaffl, 2001) . Primers used in qPCR experiments are listed in Supplementary Table 2 .
Protein expression analysis PC-146b, PC-CMV-Ä , -146b, TPC-1, and BCPAP cells were seeded at density of 1 Â 10 6 cells/plate, trypsinized and lysed in the presence of a 10-ml cocktail of protease inhibitors. Nuclear and cytoplasmic fractions were isolated with a ProteoJET Cytoplasmic and Nuclear Protein Extraction Kit (Fermentas, Glen Burnie, MD, USA) according to the manufacturer's instructions. Total protein (30-40 mg) or proteins from the nuclear/cytoplasmic fraction (15 mg) were separated by 10% polyacrylamide gel electrophoresis (PAGE) and then transferred onto nitrocellulose membranes (Hybond-ECL, GE HealthCare, Buckinghamshire, England). Membranes were incubated with monoclonal anti-SMAD4 antibody (sc-7966) or CYCLIN D1 (sc-753) from Santa Cruz BioTechnology Inc. (Santa Cruz, CA, USA), and anti-NIS antibody, and visualized using an Enhanced ChemoLuminescence kit (ECL, GE HealthCare) according to the manufacturer's instructions. The monoclonal anti-a-tubulin (sc-5286) and polyclonal anti-LAMIN A (sc-20680) antibodies (Santa Cruz BioTechnology) were used to normalize the protein input and as a control of fraction separation.
Immunofluorescence TPC-1 cells were plated onto glass coverslips in 6-well plates at densities of 3 Â 10 4 cells/well and were transfected 24 h later with anti-miR-146b. After treatment with rTGF-b1, the cells were fixed in 4% paraformaldehyde in phosphate-buffered saline, and permeabilized with 0.1% Triton X-100. Cells subsequently were incubated with anti-Smad4 antibody (diluted 1:100) followed by conjugation with Alexa-Fluor 588-anti-mouse IgG (diluted 1:400, Invitrogen). Nuclei were RNase treated and stained with 20 mg/ml propidium iodide (PI; Sigma-Aldrich, St Louis, MO, USA). Fluorescence was observed using a Nikon Eclipse TE300 Confocal Laser Microscope (Nikon Instruments Inc., Melville, NY, USA) and imaged at Â 60 optical magnification.
Cell-cycle analysis PC-CMV-+ and PC-CMV-146b cells were plated in 6-well plates at densities of 5 Â 10 5 cells/well. After 24 h, the complete media were replaced with media lacking fetal bovine serum (FBS) and TSH for synchronization in the G 0 /G 1 phase. After 24 h, FBS and TSH were added to the cultures to promote cell-cycle reentry, and the TGF-b-treated group was stimulated. A separate subset of cells (denoted TSH(À)) was maintained without TSH. Cells were collected at times 0, 3, 6 and 12 h for cell-cycle analysis by flow cytometry. Cells were washed, fixed in ice-cold 75% ethanol in phosphate-buffered saline, counted, treated with 20 mg/ml RNase, and stained with PI. Cell-cycle reentry was measured by flow cytometry using a Guava EasyCyte Mini System (Guava Technologies, Billerica, MA, USA). Data were gated using width and pulse area to exclude doublets.
Cell death analysis PC-CMV-+, PC-CMV-146b, and TPC-1 cells were seeded in 6-well plates at densities of 5 Â 10 5 cells/well. TPC-1 cells were transfected with anti-miR-146b or transfection reagent alone (mock). After 24 h of transfection (TPC-1 cells) or seeding (PC-CMV cells), the culture was treated or not with rTGF-b1. After 24 h of treatment, cells were collected by trypsinization and cell death was analyzed using Annexin-V FITC Kit (Invitrogen) according to the manufacturer instructions.
Cell proliferation assays
For PC-CMV-+, -146b, TPC-1, and BCPAP cell counting, 5 Â 10 4 cells/well were seeded into 6-well plates. TPC-1 and BCPAP cells were transfected with anti-miR-146b or transfection reagent alone (mock). Cells were counted at indicated times using a hemacytometer, and the average cell number from triplicate measurements was determined. For the MTT assay, 3 Â 10 4 cells/well were seeded in quintuplicates miR-146b-5p disrupts TGF-b signal transduction MV Geraldo et al in 96-well plates. After 24 h, 0.125 mg/ml MTT (Amresco, Solon, OH, USA) was added to the culture. The medium was removed after 3 h, and the cells were solubilized in 100 ml of 0.04 M HCl in isopropanol and measured at A 595 in a spectrophotometer (Spectra Max Plus, Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis
The results of proliferation assays and qPCR are presented as the mean±s.d. Data were submitted to Student's t-tests to compare results between two groups or to twoway ANOVA, followed by Bonferroni tests, for multiple comparisons (GraphPad Prism Software version 5.00, San Diego, CA, USA). Differences were considered significant at Po0.05.
